Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 25,482 shares of the company's stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $15.03, for a total value of $382,994.46. Following the sale, the insider now owns 135,974 shares of the company's stock, valued at $2,043,689.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Mineralys Therapeutics Stock Down 0.8 %
Shares of Mineralys Therapeutics stock opened at $14.04 on Friday. Mineralys Therapeutics, Inc. has a twelve month low of $5.85 and a twelve month high of $16.91. The company has a fifty day moving average price of $12.90 and a 200 day moving average price of $12.60.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.10). During the same period in the prior year, the firm earned ($0.31) earnings per share. Equities research analysts expect that Mineralys Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.
Institutional Trading of Mineralys Therapeutics
War on Elon Escalates…
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Mineralys Therapeutics during the 3rd quarter valued at $110,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Mineralys Therapeutics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company's stock valued at $116,000 after acquiring an additional 3,732 shares in the last quarter. Bellevue Group AG acquired a new position in shares of Mineralys Therapeutics in the first quarter worth about $119,000. Federated Hermes Inc. boosted its holdings in Mineralys Therapeutics by 100.0% in the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock valued at $140,000 after purchasing an additional 6,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Mineralys Therapeutics during the 2nd quarter valued at approximately $145,000. Hedge funds and other institutional investors own 84.46% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research report on Thursday, October 31st.
Read Our Latest Stock Report on Mineralys Therapeutics
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
